Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

ABLYNX (D) : RECEIVES EUR 5 MILLION IN MILESTONE PAYMENT FROM ALZHEIMER'S DISEASE COLLABORATION WITH BOEHRINGER INGELHEIM

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/27/2011 | 07:05am CEST

GHENT, Belgium, 27 June 2011 - Ablynx [Euronext Brussels: ABLX] today announced that it has earned a ?5 million milestone payment following Boehringer Ingelheim's decision to initiate development  with the lead Nanobody candidate that was selected in May 2010.

 

In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies against a single disease target. The collaboration has a potential value of $265 million in upfront and milestone payments plus undisclosed royalties on product sales. Boehringer Ingelheim is solely responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.

 

"We are delighted that Boehringer Ingelheim is making further progress with the Nanobody lead candidate which has the potential to be a first-in-class therapy for Alzheimer's disease and we look forward to this product advancing into the clinic in 2012. This is the second milestone payment that we have received as part of our Alzheimer's research collaboration with Boehringer Ingelheim," said Dr. Edwin Moses, Chairman and CEO of Ablynx. He added: "This programme illustrates the wide applicability and advantages of our Nanobody platform in addressing diseases as complex as Alzheimer's."

 

 

For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  [email protected]:
mailto:[email protected]

 

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  [email protected] :
mailto:[email protected]%20

 

Complete version of the press release:
http://hugin.info/137912/R/1526010/461786.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE

HUG#1526010
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
04/19ABLYNX : 19/04/2018 publication in accordance with article 14 of the belgian law..
PU
04/19ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
04/19ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
04/17Sanofi in talks to sell generics arm to Advent for 1.9 billion euros
RE
04/17ABLYNX : 17/04/2018 publication in accordance with article 14 of the belgian law..
PU
04/17ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
04/17ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
AQ
04/17ABLYNX : Threshold crossings
CO
04/12ABLYNX : 12/04/2018 publication in accordance with article 14 of the belgian law..
PU
04/12ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
More news
News from SeekingAlpha
03/26Ablynx's vobarilizumab flunks mid-stage lupus study 
03/02Mid-stage study underway in Japan for Ablynx ALX-0171 in RSV 
02/22Ablynx NV reports FY results 
01/30YOUR DAILY PHARMA SCOOP : Sanofi To Acquire Ablynx, PTC Therapeutics Announces D.. 
01/22ABLYNX : Novo Offer Undervalues The Company 
Financials (€)
Sales 2018 64,5 M
EBIT 2018 -43,8 M
Net income 2018 -60,3 M
Finance 2018 92,1 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 50,7x
EV / Sales 2019 20,1x
Capitalization 3 362 M
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 44,4 €
Spread / Average Target -0,59%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Russell G. Greig Chairman
Wim Ottevaere Chief Financial Officer
Robert K. Zeldin Chief Medical Officer
Robert Freisen Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX115.64%4 131
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.09%14 493
NEKTAR THERAPEUTICS44.36%13 873